Eidos Therapeutics Inc (NASDAQ:EIDX) – Equities researchers at Svb Leerink reduced their FY2020 EPS estimates for Eidos Therapeutics in a research note issued on Wednesday, March 27th, Zacks Investment Research reports. Svb Leerink analyst M. Foroohar now anticipates that the company will earn ($1.85) per share for the year, down from their previous forecast of ($1.54).
Several other research firms also recently weighed in on EIDX. Zacks Investment Research downgraded Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. BTIG Research assumed coverage on Eidos Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $38.00 price target for the company. JPMorgan Chase & Co. upgraded Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 27th. Finally, BMO Capital Markets assumed coverage on Eidos Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $28.00 price target for the company. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $28.57.
Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings data on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.01).
In related news, CFO Christine Siu sold 11,913 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $19.66, for a total transaction of $234,209.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jonathan C. Fox sold 5,000 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $23.11, for a total value of $115,550.00. The disclosure for this sale can be found here.
Large investors have recently added to or reduced their stakes in the stock. Wexford Capital LP raised its holdings in Eidos Therapeutics by 100.0% during the 4th quarter. Wexford Capital LP now owns 40,000 shares of the company’s stock valued at $550,000 after buying an additional 20,000 shares during the period. BlackRock Inc. raised its holdings in Eidos Therapeutics by 385.1% during the 3rd quarter. BlackRock Inc. now owns 727,698 shares of the company’s stock valued at $7,264,000 after buying an additional 577,698 shares during the period. Sphera Funds Management LTD. raised its holdings in Eidos Therapeutics by 191.1% during the 3rd quarter. Sphera Funds Management LTD. now owns 31,522 shares of the company’s stock valued at $315,000 after buying an additional 20,694 shares during the period. Vanguard Group Inc raised its holdings in Eidos Therapeutics by 297.3% during the 3rd quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock valued at $1,983,000 after buying an additional 148,673 shares during the period. Finally, Aisling Capital Management LP purchased a new stake in Eidos Therapeutics in the fourth quarter worth $15,461,000. Institutional investors own 30.15% of the company’s stock.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Recommended Story: Analyzing a company’s cash flow statement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.